Multi-omics pan-cancer analyses identify MCM4 as a promising prognostic and diagnostic biomarker

Yanxing Li, Wentao Gao, Zhen Yang, Zhenwei Hu, Jianjun LiScientific 2024 · DOI

TL;DR

This study presents a comprehensive pan-cancer analysis of MCM4, a key protein in DNA replication, revealing its significant role in the development, prognosis, and diagnosis of various cancers. The findings highlight MCM4 as a promising pan-cancer biomarker with potential implications for targeted therapies and personalized medicine.

What Problem Does This Paper Address?

Cancer remains a major global health challenge, and despite advances in treatment, a deeper understanding of its underlying mechanisms and the identification of reliable biomarkers are crucial for improving patient outcomes. While MCM4, a component of the DNA replication machinery, has been implicated in some cancers, a comprehensive, multi-omics analysis across a wide spectrum of cancer types has been lacking. This study aims to fill this knowledge gap by investigating MCM4's role in oncogenesis, prognosis, and diagnosis across numerous cancers, leveraging diverse biological data.

Methods

The researchers employed a multi-omics approach, integrating various bioinformatic tools and publicly available datasets. Key methods included:

  • Molecular Phylogenetic Analysis: To understand the evolutionary relationships of MCM4.
  • Expression Analysis: Using databases like TIMER2 and GEPIA2 to analyze differential mRNA and protein expression levels of MCM4 in tumor versus normal tissues, and across different pathological stages.
  • Cancer Dependency Analysis: Utilizing the DepMap database to assess the essentiality of MCM4 in cancer cell lines through CRISPR-Cas9 and RNAi assays.
  • Genetic Alteration Analysis: Employing cBioPortal to investigate somatic mutations and alterations in the MCM4 gene across various cancers.
  • Protein Phosphorylation Analysis: Using UALCAN to quantify the levels of total and phosphorylated MCM4 protein.
  • Molecular and Immune Subtype Analysis: Leveraging the TISIDB database to explore the association of MCM4 expression with different cancer subtypes.
  • Immune Infiltration Analysis: Using the TIMER2 webserver to investigate correlations between MCM4 expression and the infiltration of various immune cells.
  • PPI and GGI Network Analysis: Constructing protein-protein interaction (PPI) and gene-gene interaction (GGI) networks to identify MCM4's molecular partners and pathways.
  • Functional Enrichment Analysis: Employing KEGG and GO databases to understand the biological processes and pathways associated with MCM4.
  • Survival Analysis: Using GEPIA2 to generate Kaplan-Meier curves to assess the prognostic value of MCM4 expression.
  • Receiver Operating Characteristic (ROC) Analysis: To evaluate the diagnostic potential of MCM4.
  • Drug Sensitivity Analysis: Utilizing GSCALite to investigate the relationship between MCM4 and sensitivity to various anticancer drugs.

Datasets

The study utilized several publicly available datasets, including:

  • TCGA (The Cancer Genome Atlas): A comprehensive resource for genomic and molecular data from various cancer types.
  • GTEx (Genotype-Tissue Expression): Used for normal tissue expression data when TCGA lacked sufficient controls.
  • CPTAC (Clinical Proteomic Tumor Analysis Consortium): For protein expression analysis.
  • HPA (Human Protein Atlas): For immunohistochemistry (IHC) data and subcellular localization.
  • DepMap (Cancer Dependency Map): For cancer cell line dependency data.
  • cBioPortal: For genetic alteration analysis.
  • UALCAN: For protein phosphorylation analysis.
  • TISIDB: For molecular and immune subtype analysis.
  • TIMER2: For expression analysis and immune infiltration.
  • GEPIA2: For expression analysis and survival analysis.
  • STRING: For PPI network construction.
  • GeneMANIA: For GGI network construction.
  • GSCALite: For drug sensitivity analysis.

Key Insights and Ideas

  • MCM4 is a Pan-Cancer Player: The study strongly suggests MCM4 isn't just important in one or two cancers, but plays a role across a broad spectrum, making it a potential pan-cancer target.
  • DNA Replication Link is Key: MCM4's fundamental role in DNA replication is directly tied to its oncogenic potential, with its dysregulation driving uncontrolled cell proliferation.
  • Beyond Gene Expression: The analysis goes beyond simple expression levels, incorporating genetic mutations, phosphorylation states, and interactions with other genes to paint a more complete picture of MCM4's function.
  • Immune System Crosstalk: MCM4's expression is significantly correlated with immune cell infiltration patterns, suggesting it influences the tumor microenvironment and potentially impacts immunotherapy response.
  • Diagnostic and Prognostic Potential: The robust performance in ROC analyses and survival curves indicates MCM4's promise as both a diagnostic marker and a prognostic indicator across many cancer types.

Key Results

  • Upregulated Expression: MCM4 expression was significantly upregulated in a majority of the 22 cancer types analyzed compared to normal tissues.
  • Essentiality in Cancer Cells: MCM4 was found to be essential for the survival and proliferation of various cancer cell lines, as demonstrated by CRISPR-Cas9 and RNAi experiments.
  • Genetic Alterations: MCM4 exhibits frequent mutations and copy number alterations across different cancers, with UCS showing the highest mutation rate.
  • Phosphorylation Patterns: Elevated phosphorylation levels of MCM4 were observed at specific sites in several cancer types, suggesting post-translational modifications play a role in its function.
  • Prognostic Value: Increased MCM4 expression was associated with unfavorable overall survival (OS) and disease-free survival (DFS) in multiple cancer types.
  • Diagnostic Accuracy: MCM4 demonstrated high diagnostic accuracy (AUC > 0.7) in 19 out of 29 analyzed cancers, with particularly strong performance in CESC, LAML, and OV.
  • Immune Correlations: MCM4 expression showed significant positive correlations with cancer-associated fibroblast and myeloid-derived suppressor cell infiltration, and negative correlations with natural killer T cell infiltration.

Limitations and Future Work

The authors acknowledge several limitations:

  • Data Completeness: Incomplete normal tissue data in TCGA and missing protein expression/phosphorylation data in CPTAC for some cancer types limited the comprehensiveness of the analysis.
  • In Silico Nature: The study relied heavily on in silico data, which may not perfectly reflect real-world clinical scenarios.
  • Mechanism Elucidation: The study did not fully delve into the detailed molecular mechanisms underlying MCM4's role in cancer.

Future work should focus on:

  • Experimental Validation: Validating the findings using experimental models and clinical samples.
  • Mechanism Investigation: Further exploring the molecular mechanisms by which MCM4 influences cancer development and progression.
  • Therapeutic Strategies: Investigating MCM4 as a therapeutic target and exploring its role in drug sensitivity and resistance.

Summary updated

Abstract

Minichromosome Maintenance Complex Component 4 (MCM4) is a vital component of the mini-chromosome maintenance complex family, crucial for initiating the replication of eukaryotic genomes. Recently, there has been a growing interest in investigating the significance of MCM4 in different types of cancer. Despite the existing research on this topic, a comprehensive analysis of MCM4 across various cancer types has been lacking. This study aims to bridge this knowledge gap by presenting a thorough pan-cancer analysis of MCM4, shedding light on its functional implications and potential clinical applications. The study utilized multi-omics samples from various databases. Bioinformatic tools were employed to explore the expression profiles, genetic alterations, phosphorylation states, immune cell infiltration patterns, immune subtypes, functional enrichment, disease prognosis, as well as the diagnostic potential of MCM4 and its responsiveness to drugs in a range of cancers. Our research demonstrates that MCM4 is closely associated with the oncogenesis, prognosis and diagnosis of various tumors and proposes that MCM4 may function as a potential biomarker in pan-cancer, providing a deeper understanding of its potential role in cancer development and treatment.
BibTeX
@inproceedings{li2024multi,
  author = {Yanxing Li and Wentao Gao and Zhen Yang and Zhenwei Hu and Jianjun Li},
  title = {{Multi-omics pan-cancer analyses identify MCM4 as a promising prognostic and diagnostic biomarker}},
  booktitle = {Scientific},
  year = {2024},
  doi = {10.1038/s41598-024-57299-1},
}
Figure